PMID- 17268117
OWN - NLM
STAT- MEDLINE
DCOM- 20071019
LR  - 20191110
IS  - 1349-2365 (Print)
IS  - 1349-2365 (Linking)
VI  - 47
IP  - 6
DP  - 2006 Nov
TI  - Comparison of abciximab combined with dalteparin or unfractionated heparin in 
      high-risk percutaneous coronary intervention in acute myocardial infarction 
      patients.
PG  - 821-31
AB  - The purpose of this study was to determine the clinical outcomes of abciximab 
      combined with the low molecular weight heparin (LMWH), dalteparin, in high-risk 
      percutaneous coronary intervention (PCI) patients with acute myocardial 
      infarction (AMI). A total of 140 high-risk PCI patients with AMI were divided 
      into 2 groups: unfractionated heparin (UFH) with abciximab (group I: 70 patients, 
      58.7 +/- 10.5 years), and dalteparin with abciximab (group II: 70 patients, 59.6 
      +/- 9.8 years). Major adverse cardiac events (MACE) during hospitalization and at 
      4 years after PCI were examined. Baseline clinical characteristics, laboratory 
      findings, echocardiography parameters, and baseline angiographic characteristics 
      were not different between the 2 groups. The incidence of thrombotic total 
      occlusion lesions was 62.9% in both groups. Procedural success was achieved in 
      91.4% in group I and 90.0% in group II. Bleeding and hemorrhagic events were not 
      different between the 2 groups. No significant intracranial bleeding was observed 
      in either group. The incidence of in-hospital MACE was 7 (10.0%) in group I and 4 
      (5.7%) in group II. Four-year clinical follow-up was performed in 97% of the 
      patients. Four years after PCI, death occurred in 6 (8.6%) patients in group I 
      and in 7 (10.0%) in group II. MI occurred in 4 (5.7%) and 4 (5.7%), target vessel 
      revascularization (TVR) in 23 (32.9%) and 16 (22.9%), and bypass surgery in 3 
      (4.3%) and 1 (1.4%), respectively. Overall, a MACE occurred in 33 (47.1%) 
      patients in group I and in 26 (35.1%) patients in group II (P = 0.23). The 
      long-term clinical outcome with dalteparin combined with abciximab may be 
      comparable to that of UFH plus abciximab in high risk PCI patients with AMI.
FAU - Kim, Weon
AU  - Kim W
AD  - Heart Center of Gwangju Veterans Hospital, Gwangju, Korea.
FAU - Jeong, Myung Ho
AU  - Jeong MH
FAU - Hwang, Sun Ho
AU  - Hwang SH
FAU - Kim, Kye Hun
AU  - Kim KH
FAU - Hong, Young Joon
AU  - Hong YJ
FAU - Ahn, Young Keun
AU  - Ahn YK
FAU - Kim, Wan
AU  - Kim W
FAU - Cho, Jeong Gwan
AU  - Cho JG
FAU - Park, Jong Chun
AU  - Park JC
FAU - Kang, Jung Chaee
AU  - Kang JC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Japan
TA  - Int Heart J
JT  - International heart journal
JID - 101244240
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Anticoagulants)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 9005-49-6 (Heparin)
RN  - S79O08V79F (Dalteparin)
RN  - X85G7936GV (Abciximab)
SB  - IM
MH  - Abciximab
MH  - *Angioplasty, Balloon, Coronary
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Anticoagulants/*administration & dosage
MH  - Blood Loss, Surgical/prevention & control
MH  - Coronary Angiography
MH  - Dalteparin/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Immunoglobulin Fab Fragments/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*surgery
MH  - Postoperative Complications
EDAT- 2007/02/03 09:00
MHDA- 2007/10/20 09:00
CRDT- 2007/02/03 09:00
PHST- 2007/02/03 09:00 [pubmed]
PHST- 2007/10/20 09:00 [medline]
PHST- 2007/02/03 09:00 [entrez]
AID - JST.JSTAGE/ihj/47.821 [pii]
AID - 10.1536/ihj.47.821 [doi]
PST - ppublish
SO  - Int Heart J. 2006 Nov;47(6):821-31. doi: 10.1536/ihj.47.821.